MGH Study Finds Ace Inhibitors Underprescribed For Heart Failure

November 24, 1997

A new report from the Massachusetts General Hospital suggests that many patients with heart failure are not receiving the most up-to-date medications for their condition. The study in the November 24 Archives of Internal Medicine finds that, from 1989 to 1994, angiotensin-converting enzyme (ACE) inhibitors were prescribed for fewer than half the patients that could benefit from the drugs. "Several studies during the past ten years have shown that ACE inhibitors reduce death and disability associated with heart failure," says Randall Stafford, MD, PhD, first author of the study. "My colleagues and I were quite surprised to see how seriously these drugs -- that have few negative side effects -- were being underused."

Heart failure results when the heart muscle cannot efficiently pump blood through the body. Fluids back up in the lungs or other parts of the body -- causing a vicious cycle in which pressures within the heart rise and the already weakened organ undergoes further damage by trying to pump against this increased pressure. The condition can result from a heart attack, damaged heart valves, high blood pressure, lung disease, infection or several other causes. In many cases, it can be treated or even reversed by appropriate therapeutic interventions. The American Heart Association estimates that 4.7 million Americans are affected by heart failure, the single most frequent cause of hospitalization for those 65 and older, and 250,000 die each year.

ACE inhibitors act both by relaxing the arteries, which lowers blood pressure and makes the heart's job easier, and by adjusting levels of hormones that control blood pressure and heart function. The first ACE inhibitor, captopril, was introduced in the 1970s to treat high blood pressure, and numerous studies during the 1980s and 1990s strongly indicated that these drugs reduced death and disability in patients with heart failure. In recent years, both the American College of Cardiology and the U.S. Agency for Health Care Policy and Research have issued clinical guidelines recommending ACE inhibitors to treat heart failure. In general, the guidelines suggest that ACE inhibitors be tried in a broad range of patients with mild to severe heart failure before other types of medication, such as digoxin and diuretics. Stafford's team found that more than twice as many heart failure patients were taking diuretics in 1994 as were taking ACE inhibitors.

The MGH team reviewed information from the 1989 through 1994 National Ambulatory Medical Care Surveys. More than 9,500 physicians from many specialties and geographic areas reported on the services they provided during all patient visits during a randomly selected week. The researchers found that prescriptions for ACE inhibitors increased from 24 percent of heart failure visits in 1989 to 31 percent in 1994, an increase that was much lower than expected with the growing evidence of the medications' effectiveness. They also found that ACE inhibitor prescriptions were more likely in visits to cardiologists, in the Midwest, for white patients, for privately insured patients and for male patients.

"Although we don't have a specific percentage of heart failure patients that should be receiving ACE inhibitors, I'd estimate it's probably between 50 and 75 percent, much more than we found in this study," Stafford says. "We're not sure why they're being so seriously underprescibed. It could be a combination of lack of knowledge, an unrealistic assessment of their negative side effects -- of which there are very few -- and a lack of attention to preventive measures," he adds.

Stafford notes that there could have been an increase in ACE inhibitor usage in the three years after those examined in this study, but that additional efforts to educate both physicians and patients about their usefulness are probably needed. The variations seen in the use of ACE inhibitors by physician specialty, race and geographic region suggest that the recommended practices are not being uniformly applied, he says.

Stafford's coauthors are Demet Saglam, MA, and David Blumenthal, MD, MPP, director of the MGH Health Policy Research and Development Unit. Information in this study was originally presented last fall at the 1996 American Heart Association meeting. The study was supported by grants from the Agency for Health Care Policy and Research and the National Heart, Lung and Blood Institute.




Massachusetts General Hospital

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.